Pharsight

Makena generic

Makena is a drug owned by Covis and authorized for market use on 3rd February 2011. The active ingredient in Makena is hydroxyprogesterone caproate. Makena has a total of 12 drug patents, none of which have expired yet.

When will Makena generic be available?

The generic version of Makena is expected to be released after 2nd May 2036. This date is due to the patent titled 'Methods of reducing risk of preterm birth', which will expire on 2nd May 2036.

Makena uses

Makena, containing hydroxyprogesterone caproate, is used for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. Makena is available in solution; subcutaneous, solution; intramuscular dosage forms.

Makena patent expiration

Makena owns a total of 12 patents, with the latest patent 'Methods of reducing risk of preterm birth' set to expire on 2nd May 2036. The release date for Makena generic is expected to be after this date. Below are the details of the patent:

EPO Oppostions filed on Makena

Makena dosage

Want to ask something?